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Abstract
Objectives: Induction therapy with rabbit antithymocyte
globulin is frequently used in kidney transplant
recipients and contributes to regulating the humoral
alloantibody response. However, the effect of rabbit
antithymocyte globulin on B-cell subpopulations,
including plasma cells, has not been previously studied
in humans in vivo.
Materials and Methods: We prospectively studied a
cohort of 39 adult kidney transplant recipients. Twenty
patients received rabbit antithymocyte globulin as
induction therapy. Peripheral blood samples were
obtained pretransplant and at 6 and 12 months
posttransplant. T and B cells were acquired by flow
cytometry.
Results: Total lymphocytes and CD3 and CD4 cells
significantly decreased at 6 and 12 months only 
in patients who received rabbit antithymocyte 
globulin. In contrast, the CD19 population did 
not change after rabbit antithymocyte globulin
induction. One-year circulating plasma cells remained
significantly lower than pretransplant levels in
patients who received rabbit antithymocyte globulin.
We observed sig nificant differences in plasma cell
numbers at 12 months after transplant between
patients who received rabbit antithymocyte 
globulin and those patients who did not receive 
it (median of 5 and interquartile range of 3-17 vs
median of 25 and interquartile range of 12-35;
P = .001). 
Conclusions: Rabbit antithymocyte globulin induction
leads to a late reduction in the number of circulating
plasma cells at 1 year after kidney transplant. This
effect can contribute to down-regulation of the
humoral alloantibody response.
Key words: Induction, Lymphocyte subpopulation, Renal
transplantation 
Introduction
Induction therapy with an interleukin 2 receptor
antagonist or a lymphocyte-depleting agent has been
strongly recommended as part of the initial immuno -
suppressive regimen in kidney transplantation to
modulate or deplete T-cell responses while allo antigen
presentation occurs.1,2 Induction drugs contribute to
reducing acute rejection rate and to improving graft
survival compared with placebo or no induction,
especially in high-risk patients.3-5 Among lymphocyte-
depleting agents, rabbit antithymocyte globulin
(rATG) is the most frequently used induction drug in
the United States and the second most frequently used
in Europe and Australia/New Zealand.6-9 Differences
in prescription rates among different countries and
centers point to no definite indications for selecting
rATG instead of other induction agents in a specific
transplant recipient. However, common consensus
and guidelines suggest using rATG at least in
patients with a higher risk of rejection and/or
delayed graft function.1,8,10
In the past decade, the humoral alloimmune
response against the graft has regained importance.
On the one hand, the significant role of donor-specific
antibodies has been recognized in the development of
antibody-mediated rejection (AbMR) that drives
further kidney graft loss.11,12 On the other hand,
several studies have demonstrated a specific B-cell
subpopulation signature in tolerant patients.13-17 In
relation to both aspects, we suspected that rATG
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could influence the humoral side of the alloimmune
response. First, rATG is used to prevent and treat
AbMR and contributes to reducing donor-specific
antibodies and HLA antibodies in kidney and heart
transplant recipients.10,18-21 Second, rATG has become
a cornerstone agent to promote tolerance in both
animal models22-24 and humans.25-27 Although it is
well known that T-cell depletion constitutes the main
mechanism of action of rATG, it also interacts with
different immune and nonimmune cell types, such as
B cells, natural killer cells, and endothelial cells.28,29
Thus, rATG triggers complement-independent
apoptosis of naive, activated, and plasma B cells in
vitro.30 However, the effect of rATG on B-cell
subpopulations, including plasma cells, has not been
previously studied in humans in vivo.31 Our aim was
to analyze changes in B-cell subpopulations in
kidney transplant recipients treated with rATG as
induction therapy.
Materials and Methods
A cohort of 39 consecutive adult kidney transplant
recipients, with procedures performed at the
Marqués de Valdecilla University Hospital from
February 2015 to January 2016, was prospectively
studied during the first 12 months after transplant.
Four patients were excluded due to pretransplant use
of rituximab or because they received rATG
(Thymoglobulin; Genzyme Corporation, Cambridge,
MA, USA) to treat acute rejection. Standard initial
immunosuppression consisted of tacrolimus, myco -
phenolate mofetil, and prednisone. Twenty patients
received rATG as induction therapy due to
simultaneous pancreas-kidney transplant (n = 3),
donation after cardiac death (n = 11), high risk of
delayed graft function (n = 19), and/or hyper -
sensitization (n = 5). Five patients received induction
therapy with basiliximab. Relevant information
about recipient, donor, and transplant characteristics
was extracted from the prospectively maintained
database of renal transplant patients at our center.
One-year estimated glomerular filtration rate (eGFR)
was calculated using the CKD-EPI equation.
Diagnosis of acute rejection was proven with biopsy.
This study was conducted according to the
guidelines of the Declaration of Helsinki and was
approved by the ethics committee of our hospital. All
patients included in the study gave written informed
consent.
Peripheral blood samples in EDTA containers
were obtained pretransplant and at months 6 and 12
after transplant. Flow cytometry was performed
according to standard protocol by using CytoFLEX
(Beckman Coulter, Fullerton, CA, USA). Blood cells
were freshly stained with the following monoclonal
antibodies: CD27-FITC clone M-T271, CD138-FITC
clone MI15, CD24-PE clone ML5, CD268-PE clone
7H22-E16, and immunoglobulin M-APC clone 
G20-127 (from BD Biosciences, San Jose, CA, USA);
CD19-PC5.5 clone J3-119 (from Beckman Coulter);
CD38-PC7 clone HIT2, CD5-APC clone UCHT2,
CD10-APC Cy7 clone HI10a, CD25-Pacific Blue clone
BC96, and IgD-Brilliant Violet 510 clone IA6-2 (from
BioLegend, San Diego, CA, USA); and CD27-APC
Cy7 clone M-T271, CD21-VioBlue clone HB5, and
CD20-VioGreen clone REA780 (from Miltenyi,
Bergisch Gladbach, Germany). These were used to
identify different B-cell subsets.
Naïve B cells were defined as CD19+IgD+CD27-
(CD19-positive, immunoglobulin D positive, CD27
negative), different subsets of transitional B cells as
CD19+CD24+CD38+ (CD19, CD24, CD38 positive),
unswitched memory B cells as CD19+IgD+CD27+
(CD19, immunoglobulin D positive, CD19 positive),
switched memory B as CD19+IgD-CD27+ (CD19
positive, immunoglobulin D negative, CD27 positive),
plasmablasts as CD19lowCD20-CD27+CD38high, 
and plasma cells as CD19-CD20-CD27highCD38high
CD138+. 
Statistical analyses
We performed statistical analyses using SPSS version
15.0 (SPSS Inc, Chicago, IL, USA). According to the
Kolmogorov-Smirnov test, all continuous variables
did not show normal distribution. Therefore, non -
parametric tests were used for all continuous
variables. Continuous variables are shown as
medians and interquartile ranges (IQR), whereas
qualitative variables are shown as total number of
observations and percentages.
Results
Main patient characteristics are shown in Table 1.
Median rATG dose was 6.6 mg/kg (IQR, 5.1-8.0
mg/kg). Lymphocyte subpopulation changes are
reported in Table 2 (no rATG group) and Table 3 (rATG
group) and in Figures 1 and 2. Total lymphocytes, CD3
cells, and CD4 cells were significantly decreased at 6
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and 12 months only in the group of patients who
received rATG. In contrast, the CD19 population did
not change at 6 and 12 months after rATG induction.
Of note, 1-year circulating plasma cells remained
significantly lower than pretransplant levels only in
patients who received rATG. Other B-cell sub -
populations (naïve, unswitched/switched memory
B cells, mature) did not change significantly after
rATG induction therapy.
We observed significant differences in plasma cell
numbers at 12 months after transplant between
patients who received rATG and patients who did
not receive it (median and IQR of 5 [3-17] vs 25 
[12-35]; P = .001). In contrast, we observed no
significant differences in plasma cells pretransplant
(median and IQR of 22 [12-84] vs 39 [6-50]; P = .461)
or at 6 months (median and IQR of 21 [8-30] vs 24 [10-
35]; P = .433) between both groups of patients.
Variables related to 1-year levels of peripheral
blood plasma cells in patients treated with rATG
were the number of circulating CD4 cells at 12
months (r = 0.522, P = .022), the number of circulating
CD19 cells (r = 0.691, P = .001), and eGFR at 12
months (r = 0.648, P = .003). However, recipient age
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table 1. Main Patient Characteristics
No rATG rATG P Value 
(n = 15) (n = 20) (Mann-Whitney)
Recipient age, y 53 (44-65) 52 (41-60) .499
Male recipient 60% 60% 1.000
SPK 0% 15% .117
Hypersensitized 0% 25% .036
Donor age, y 53 (48-59) 51 (38-64) .681
DCD 0% 55% .001
cPRA > 20% 0% 25% .036
Mismatches, No. 4 (4-5) 5 (3-5) .882
Retransplant 13.3% 25.0% .393
Cold ischemia time, min 19 (17-21) 12 (8-19) .074
DGF 33.3% 30.0% .833
1-year creatinine, 
mg/dL 1.37 (1.00-1.95) 1.37 (1.04-1.91) .934
1-year eGFR, 
mL/min/1.73 m2 69.4 (38.9-75.8) 56.5 (40.5-81.6) .856
1-year proteinuria, 
mg/day 270 (206-945) 384 (221-846) .784
1-year acute rejection 20.0% 25.0% .727
1-year tacrolimus 100% 95% .380
1-year mycophenolate 93.3% 95.0% .833
1-year mTOR inhibitor 0% 5% .380
1-year prednisone 86.7% 80.0% .605
table 2. Evolution of Peripheral Blood Lymphocyte Subpopulation in Patients
Not Receiving Induction With Rabbit Antithymocyte Globulin (n = 15)
Subpopulation Median (Interquartile Range)
Pretransplant 6 Months 12 Months
Total 
lymphocytes 1515 (1182-1953) 1724 (1243-1994) 1630 (1360-2294)
CD3 1116 (920-1648) 1435 (910-1632) 1254 (1014-1975)
CD4 800 (549-1008) 756 (453-953) 757 (608-892)
CD19 90 (63-229) 91 (41-165) 92 (69-163)
Naïve 8 (2-33) 5 (1-22) 13 (7-30)
Unswitched 
memory B 6 (4-11) 6 (4-15) 7 (5-9)
Switched 
memory B 15 (6-26) 12 (5-19) 18 (9-41)
Mature B 6 (1-14) 2 (1-4)a 4 (2-12)
Plasma cells 39 (6-50) 24 (10-35) 25 (12-35)
Abbreviations: cPRA, calculated panel reactive antibody; DCD, donation after
cardiac death; DGF, delayed graft function; eGFR, estimated glomerular
filtration rate; mTOR, mammalian target of rapamycin; rATG, rabbit
antithymocyte globulin; SPK, simultaneous pancreas-kidney transplant
Data are shown as frequency (qualitative variables) or median and
interquartile range (quantitative variables).
aP = .030 for pretransplant vs 6 months (Wilcoxon test).
table 3. Evolution of Peripheral Blood Lymphocyte Subpopulation in
Patients Receiving Induction With Rabbit Antithymocyte Globulin (n = 20)
Subpopulation Median (Interquartile Range)
Pretransplant 6 Months 12 Months
Total 
lymphocytes 1626 (898-2063) 681 (555-1294)a 943 (530-1457)c
CD3 1322 (707-1627) 524 (412-959)a 617 (343-984)b
CD4 717 (446-931) 161 (95-270)a 180 (130-306)b,c
CD19 97 (51-192) 42 (33-185) 87 (53-152)
Naïve 12 (5-19) 7 (2-23) 8 (4-20)
Unswitched 
memory B 5 (3-28) 5 (2-16) 10 (2-22)
Switched 
memory B 14 (5-25) 12 (3-35) 14 (4-19)
Mature B 3 (2-7) 2 (0.4-8) 5 (3-12)
Plasma cells 22 (12-84) 21 (8-30) 5 (3-17)d,e
aP = .05, pretransplant vs 6 months; bP < .05, pretransplant vs 12 months; 
cP < .05, 6 months vs 12 months; dP = .007, pretransplant vs 12 months; 
eP = .015, 6 months vs 12 months (Wilcoxon test).
Figure 1. Changes in Lymphocyte Subpopulation (Total Lymphocytes and
CD3, CD4, and CD19 Cells) in Peripheral Blood From Patients Treated and
Not Treated With Rabbit Antithymocyte Globulin
(P = .393), sex (P = .196), steroid use (P = .885),
calculated panel reactive antibody > 20% (P = .262),
donation after cardiac death (P = .968), and acute
rejection (P = .219) were not significantly associated
with peripheral blood plasma cell level. After linear
regression analysis, CD19 (0.076, 95% confidence
interval [95% CI], 0.026-0.127; P = .006) and eGFR
(0.167, 95% CI, 0.039-0.295; P = .014) remained
independently related to peripheral blood plasma
cell level at 12 months.
Variables related to levels of 1-year circulating
plasma cells in patients not treated with rATG were
the number of circulating CD4 and CD19 cells at 
12 months (r = 0.763, P = .001 and r = 0.597, P = .024,
respectively). However, eGFR at 12 months (P = .751),
recipient age (P = .082), sex (P = .898), steroid use 
(P = .549), and acute rejection (P = .555) were not
related.
Discussion
Although it is well known that rATG exerts its main
immunosuppressive effects by depleting T cells,
some of these effects are driven through B-cell
depletion and down-regulation of cell surface
expression of some leukocyte adhesion molecules
(previously reviewed28,29). The influence on the 
B-cell population is due to the presence of B cells and
some B-cell surface antigens in the thymic
preparation used for rATG production. In this sense,
Zand and associates reported that CD20-positive B
cells could be found in the pediatric thymus.30
Consequently, rATG preparations have different
antibodies against B-cell populations that can
promote apoptosis in these cells in vitro at clinically
relevant concentrations.30-33 The influence of rATG
on B cells has been demonstrated in animal models.
Préville and associates reported that rATG treatment
induced a partial B-cell depletion in a cynomolgus
monkey model.34 However, this effect has not been
consistently shown in in vivo studies performed in
humans. Although some authors detected some
depletion of B cells or B-cell subsets in humans,
mainly in the initial months,35-37 we and others found
no significant changes in B-cell lymphocytes or in 
B-cell subsets.38,39 Differences in transplant patient
characteristics, rATG dose, sample timing, and batch-
to-batch variations in the quantity of B-cell antigens
in the thymic preparation can partly explain these
differences.30,35-39
Similar findings would be expected regarding
plasma cells. Plasma cell antigens, mainly CD138, are
found in pediatric thymic parenchyma, and plasma
cell apoptosis induced by rATG has been reported in
in vitro studies by some but not all authors.30,33,40,41
Considering this potential role of rATG, we could
have found an early effect of rATG that reduced the
number of circulating plasma cells, but we detected
no significant change in the number of peripheral
blood plasma cells at month 6. In contrast, the main
finding of our study was that rATG induced a late
depletion on circulating plasma cells that was only
detected at month 12. No previous studies have
analyzed the long-term effects of rATG on B-cell
subsets including plasma cells. Potential mechanisms
that explain this finding are not known. On the one
hand, regarding T cells, rATG exerts a late effect that
influences the different T-cell subsets beyond the
period in which rATG can be detected in blood.42
Although not explored, a similar mechanism could
be possible for plasma cells. On the other hand, rATG
modifies the reconstitution of T-cell subpopulations
(as reviewed previously28,29,35); among them, T-
follicular helper cells have a strong influence on the
development and maintenance of human circulating
antigen-induced plasma cells.43,44 Hence, T-follicular
helper cell depletion and T-cell subset changes
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Figure 2. Changes in Number of Peripheral Blood Plasma Cells in Patients
Treated and Not Treated With Rabbit Antithymocyte Globulin
promoted by rATG could favor a late (12 month)
reduction in circulating plasma cells, whereas long-
lived plasma cells were not affected earlier (that 
is, at 6 months). Although this mechanism was not
explored in our study, the positive correlation
between CD4-positive cells and plasma cells that we
found could support this hypothesis.
Kidney transplant induction with rATG contri -
butes to the reduction of acute rejection in the short
and long term compared with placebo or no treatment
and with interleukin 2 receptor monoclonal antibodies
in high-risk patients.4,5,45-48 Because of this, current
guidelines suggest using a lymphocyte-depleting
agent for kidney transplant recipients at high
immunologic risk.1,2 This beneficial effect of rATG is
mainly explained by its potent effect on the T-cell
compartment, but a potential role in B-cell sub -
populations cannot be discarded; for example, rATG
has been used to treat and prevent AbMR.21,49 Because
rATG is preferentially used in patients with high
immunologic risk and the yearly rate of donor-specific
antibody appearance is low, until recently, it has been
difficult to demonstrate that rATG helps to reduce the
development of donor-specific antibodies. Brokhof and
colleagues reported that rATG induc tion is associated
with a lower incidence of de novo donor-specific
antibodies in moderately sensitized renal transplant
recipients.18 Because bone marrow plasma cells are the
origin of donor-specific anti bodies and circulating
plasma cells reflect this population, our finding of
lower peripheral blood plasma cells in patients who
received rATG could explain how it contributes to
controlling donor-specific antibody appearance.
As previously reported, rATG is a key component
of several immunosuppressive regimens designed to
induce tolerance in kidney transplant recipients.25-27
In these therapeutic protocols, rATG is mainly used
because it has potent unspecific immuno suppressive
effects. However, rATG may also promote some
tolerogenic mechanisms. For example, treatment
with rATG induced a significant proliferation of
regulatory T cells.50,51 Because certain B-cell sub -
populations relate to a “tolerant” state, we analyzed
changes in B-cell subsets after rATG induction.
Although we did not find an increase in the number
of näive B cells, the low number of plasma cells that
we found has also been previously related to a
tolerant situation with stable kidney graft function in
the absence of immunosuppression.16 In contrast,
patients who were treated with alemtuzumab as
induction therapy showed a “tolerant” B signature
with higher rate of näive and transitional B cells at
month 6, but this was not shown in plasma cells.52
Although kidney transplant outcomes are similar
with both induction drugs, they have different long-
term effects on B-cell subpopulations.53
Our study has several limitations. First, like in
similar single-center studies,38,39,52 the number of
patients included was low. Second, patients received
rATG due to different indications, mainly because of
high risk for delayed graft function. Interestingly, the
results did not change after exclusion of hyper -
sensitized patients whose plasma cells were not
significantly different at any moment. Last, it would
have been interesting to draw intermediate blood
samples between the transplant procedure and
month 6 to know the initial changes of B-cell subsets
due to rATG. Budget constraints required limiting
the number of samples and patients analyzed.
Conversely, the strengths of our study are its
prospective nature, the complete follow-up of all
patients up to month 12, and the significant number
of B-cell subpopulations studied.
To conclude, we analyzed the effects of rATG
induction on B-cell subpopulations, including
plasma cells, in vivo in humans for the first time. We
disclosed a not previously reported late reduction of
plasma cells induced by rATG. This effect can
contribute to diminishing the development of donor-
specific antibodies and further AbMR and graft loss,
which could also promote tolerance. Although the
underlying mechanisms are not known, T-cell
(specifically CD4-positive) depletion may interfere in
the T-B cell cooperation necessary for long-lived
plasma cell formation.
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